Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hearing On Natco Plea To Make Generic Version Of Roche, Pfizer Cancer Drugs Extended To March

This article was originally published in PharmAsia News

Executive Summary

NEW DELHI - An Indian patent office hearing on the closely watched application by Hyderabad, India-based Natco Pharma for a compulsory license to sell generic copies of Roche and Pfizer drugs to poor countries will continue next month, a spokesman for the patent office said

You may also be interested in...



Indian Court Allows Cipla to Continue Sales of Generic Roche Lung Cancer Drug Tarceva

MUMBAI - An Indian generic drug maker cannot be halted from manufacturing and selling a generic version of Roche's locally patented lung cancer drug Tarceva (erlotinib) in what a spokesman for the Mumbai-based company said was a "landmark" ruling under the country's three-year-old patent regime

Indian Court Allows Cipla to Continue Sales of Generic Roche Lung Cancer Drug Tarceva

MUMBAI - An Indian generic drug maker cannot be halted from manufacturing and selling a generic version of Roche's locally patented lung cancer drug Tarceva (erlotinib) in what a spokesman for the Mumbai-based company said was a "landmark" ruling under the country's three-year-old patent regime

India Patent Office to Make Key Decision on Export of Roche, Pfizer Cancer Drugs

NEW DELHI - India's patent office will hold hearings Feb. 28 and 29 to decide whether India's Natco Pharmaceuticals should be awarded the country's first compulsory license to make and export to Nepal generic cancer drugs patented locally by Roche and Pfizer

Related Content

UsernamePublicRestriction

Register

LL1121650

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel